Sponsored Links
| FDA Advisory Committee Votes In Favor Of SAPHRIS(R) (asenapine) For Acute Bipolar I Disorder And Acute Schizophrenia |
 |
 |
 |
| Medical News - Bipolar | |||
|
Schering-Plough Corporation (NYSE: SGP) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted unanimously in favor of SAPHRIS(R) (asenapine) sublingual tablets as effective and safe for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and in favor of use in acute treatment of schizophrenia in adults. Read more: Bipolar News From Medical News Today
|